AU2022422024A1 — Methods and agents for increasing rbm3 expression
Assigned to Freie Universitaet Berlin · Expires 2024-07-04 · 2y expired
What this patent protects
The invention provides agents (e.g., antisense oligonucleotides (ASOs), a CRISPR/Cas-based base editing system) capable of increasing expression of RNA-binding motif protein 3 (RBM3) by targeting a poison exon of RBM3, exon 3a, or a splice site thereof. Also disclosed are methods…
USPTO Abstract
The invention provides agents (e.g., antisense oligonucleotides (ASOs), a CRISPR/Cas-based base editing system) capable of increasing expression of RNA-binding motif protein 3 (RBM3) by targeting a poison exon of RBM3, exon 3a, or a splice site thereof. Also disclosed are methods for increasing expression of RBM3 in a cell, methods of treating or preventing a disease affected by RMB3 expression in a subject, or methods for providing neuroprotective treatment to a subject.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.